Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Under pressure at home, Belgium's leader treads a tight rope with EU partners over funds for Ukraine - 2The most effective method to Recuperate After a Dental Embed Strategy: A Far reaching Guide
- 3Honda’s Biggest Flex Isn’t Its Superbikes, It’s Selling 500K Bikes In One Month
- 4Merz: 80% of Syrians in Germany expected to return within three years
- 5Thyssenkrupp to suspend electrical steel production at French site
- Sa'ar warns German delegation: 'A Palestinian state would be a Hamas terror state'
- Old photos misrepresented as aftermath of political party supporters' brawl in Bangladesh
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- What do scientists hope to learn from NASA's historic Artemis 2 moon flyby?
- Vote In favor of Your Favored Kind Of Organic product
- First Phosphate advances battery-grade phosphate project as analysts highlight strategic Federal support
- New heart disease calculator predicts 30-year risk for young adults
- The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act.
- Extraordinary Picks for Home Apparatuses: Making Life Simpler
